PUBLICATION
Optimal combination of anti-inflammatory components from Chinese medicinal formula Liang-Ge-San
- Authors
- Lu, Z., Cao, H., Liu, D., Zheng, Y., Tian, C., Liu, S., Quan, J., Shi, L., Liu, J., Yu, L.
- ID
- ZDB-PUB-201229-24
- Date
- 2020
- Source
- Journal of ethnopharmacology 269: 113747 (Journal)
- Registered Authors
- Keywords
- Active components, Inflammation, Liang-Ge-San, Lipopolysaccharide, Orthogonal experimental design, Zebrafish
- MeSH Terms
-
- Animals
- Anti-Inflammatory Agents, Non-Steroidal/pharmacology*
- Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
- Disease Models, Animal
- Drugs, Chinese Herbal/chemistry*
- Drugs, Chinese Herbal/pharmacology*
- Drugs, Chinese Herbal/therapeutic use
- Emodin/pharmacology
- Emodin/therapeutic use
- Flavanones/pharmacology
- Flavanones/therapeutic use
- Flavonoids/pharmacology
- Flavonoids/therapeutic use
- Glucosides/pharmacology
- Glucosides/therapeutic use
- Inflammation/chemically induced
- Inflammation/drug therapy*
- Interleukin-6/genetics
- Larva/cytology
- Larva/drug effects
- Lipopolysaccharides/toxicity
- MAP Kinase Signaling System/drug effects
- Macrophages/drug effects
- Medicine, Chinese Traditional
- Myeloid Differentiation Factor 88/antagonists & inhibitors
- NF-kappa B/metabolism
- Neutrophil Infiltration/drug effects
- Neutrophils/drug effects
- Tumor Necrosis Factor-alpha/genetics
- Yolk Sac/cytology
- Yolk Sac/drug effects
- Yolk Sac/immunology
- Zebrafish
- Zebrafish Proteins/antagonists & inhibitors
- PubMed
- 33359185 Full text @ J. Ethnopharmacol.
Citation
Lu, Z., Cao, H., Liu, D., Zheng, Y., Tian, C., Liu, S., Quan, J., Shi, L., Liu, J., Yu, L. (2020) Optimal combination of anti-inflammatory components from Chinese medicinal formula Liang-Ge-San. Journal of ethnopharmacology. 269:113747.
Abstract
Ethnopharmacological relevance Liang-Ge-San (LGS), a traditional Chinese medicine (TCM) formula, is usually used in acute inflammatory diseases in China.
Aim of the study This study aims to detect the optimal combination of anti-inflammatory components from LGS.
Materials and methods Four mainly representative components (phillyrin, emodin, baicalin, and liquiritin) from LGS were chosen. The optimal combination was investigated by orthogonal design study. Zebrafish inflammation model was established by lipopolysaccharide (LPS)-yolk microinjection, and then the anti-inflammatory activities of different combinations were determined by survival analysis, changes on inflammatory cells infiltration, the MyD88/NF-κB and MAPK pathways and inflammatory cytokines production.
Results The different combinations of bioactive ingredients from LGS significantly protected zebrafish from LPS-induced inflammation, as evidenced by decreased recruitment of macrophages and neutrophils, inhibition of the MyD88/NF-κB and MAPK pathways and down-regulation of TNF-α and IL-6. Among them, the combination group 8 most significantly protected against LPS. The combination of group 8 is: 0.1 μM of emodin, 2 μM of baicalin, 20 μM of phillyrin and 12.5 μM of liquiritin.
Conclusion The optimized combination group 8 exerts the most significant anti-inflammatory activity by inhibiting the recruitment of inflammatory cells, activation of the MyD88/NF-κB and MAPK pathways and the secretion of pro-inflammatory cytokines. This present study provides pharmacological evidences for the further development of new modern Chinese drug from LGS to treat acute inflammatory diseases, but indicated the use of zebrafish in the screening of components from formulas.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping